Cystic fibrosis transmembrane conductance regulator:: Solution structures of peptides based on the Phe508 region, the most common site of disease-causing ΔF508 mutation

被引:20
|
作者
Massiah, MA [1 ]
Ko, YH [1 ]
Pedersen, PL [1 ]
Mildvan, AS [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA
关键词
D O I
10.1021/bi9903603
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most cases of cystic fibrosis (CF), a common inherited disease of epithelial cell origin, are caused by the deletion of Phe508 located in the first nucleotide-binding domain (NBF1) of the protein called CFTR (cystic fibrosis transmembrane conductance regulator). To gain greater insight into the structure within the Phe508 region of the wild-type protein and the change in structure that occurs when this residue is deleted, we conducted nuclear magnetic resonance (NMR) studies on representative synthetic 26 and 25 amino acid peptide segments. 2D H-1 NMR studies at 600 MHz of the 26-residue peptide consisting of Met498 to Ala523 in 10% DMSO, pH 4.0, at 25 degrees C show a continuous but labile helix from Gly500 to Lys522, based on both NH-NH(i,i+1) and alpha H-NH(i,i+1) NOEs. Phe508 within this helix shows only short-range (i, less than or equal to i + 2) NOEs. The corresponding 25-residue peptide lacking Phe508 also forms a labile helix from Gly500 to Lys522. However, the relative intensities of the NH-NH(i,i+1)/alpha H-NH(i,i+1) NOEs, fewer intermediate-range NOEs, and downfield alpha H and NH chemical shifts indicate a lower helical propensity of the 25-mer between residues 505 and 517, surrounding the missing residue, Phe508. 2D H-1 NMR studies of both peptides in saturating (43%) TFE reveal stable a-helices from Gly500 to Lys522, based on NH-NH(i,i+1,2,3), alpha H-NH(i,i+2,3,4), alpha H-beta H-(i,H-i+3), and weak alpha H-NH(i,i+1) NOEs. However, downfield shifts of the alpha H resonances from residues Gly500 to Ile507 and fewer intermediate-range NOEs suggest a less stable ex-helix in the 25-mer even in saturating TFE. These findings show that the Phe508 containing region of CFTR has a propensity to form an ct-helix, which is destabilized by the Delta F508 mutation found in most patients with CF, These studies have direct relevance to better understanding the CFTR misfolding problem associated with CF and to identifying chemical agents, which correct this problem.
引用
收藏
页码:7453 / 7461
页数:9
相关论文
共 50 条
  • [1] Solution structures of peptides based on PHE-508, A site of frequent mutation in cystic fibrosis transmembrane conductance regulator (CFTR).
    Massiah, MA
    Ko, YH
    Pedersen, PL
    Mildvan, AS
    BIOPHYSICAL JOURNAL, 1999, 76 (01) : A428 - A428
  • [2] The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator
    Chen, EY
    Bartlett, MC
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) : 39620 - 39627
  • [3] The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis
    Thibodeau, Patrick H.
    Richardson, John M., III
    Wang, Wei
    Millen, Linda
    Watson, Jarod
    Mendoza, Juan L.
    Du, Kai
    Fischman, Sharon
    Senderowitz, Hanoch
    Lukacs, Gergely L.
    Kirk, Kevin
    Thomas, Philip J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (46) : 35825 - 35835
  • [4] Cystic Fibrosis Transmembrane Conductance Regulator ΔF508 Heterozygosity: A Spectrum of Disease Burden
    Banipal, J.
    Icard, B. L.
    Sweet, J. M.
    Loschner, A. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [5] Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine
    Robert, Renaud
    Carlile, Graeme W.
    Liao, Jie
    Balghi, Haouaria
    Lesimple, Pierre
    Liu, Na
    Kus, Bart
    Rotin, Daniela
    Wilke, Martina
    de Jonge, Hugo R.
    Scholte, Bob J.
    Thomas, David Y.
    Hanrahan, John W.
    MOLECULAR PHARMACOLOGY, 2010, 77 (06) : 922 - 930
  • [6] Constrained bithiazoles as correctors for the ΔF508 cystic fibrosis transmembrane conductance regulator gene
    Coffman, Keith C.
    Nguyen, Huy H.
    Phuan, Puay-Wah
    Yu, Gui J.
    Bagdasarian, Alex L.
    Montgomery, Deanna
    Lodewyk, Michael W.
    Yang, Baoxue
    Yoo, Choong L.
    Verkman, Alan S.
    Tantillo, Dean J.
    Kurth, Mark J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [7] Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by the Flavonoid Quercetin Potential Use as a Biomarker of ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator Rescue
    Pyle, Louise C.
    Fulton, Jennifer C.
    Sloane, Peter A.
    Backer, Kyle
    Mazur, Marina
    Prasain, Jeevan
    Barnes, Stephen
    Clancy, J. P.
    Rowe, Steven M.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2010, 43 (05) : 607 - 616
  • [8] Autosomal dominant polycystic kidney disease (ADPKD) and ΔF508 mutation at the cystic fibrosis transmembrane conductance regulator gene.
    Peces, R
    Coto, E
    Gago, E
    Ariza, M
    Laures, AS
    Tejada, F
    Alvarez, J
    KIDNEY INTERNATIONAL, 1999, 55 (01) : 359 - 359
  • [9] Comparison of the bacterial HelA protein to the F508 region of the cystic fibrosis transmembrane regulator
    Goldman, BS
    Sherman, DA
    Kranz, RG
    JOURNAL OF BACTERIOLOGY, 1997, 179 (24) : 7869 - 7871
  • [10] Activation of endogenous Delta F508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition
    Kelley, TJ
    AlNakkash, L
    Cotton, CU
    Drumm, ML
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02): : 513 - 520